BioSpace News Archive

Foundation Medicine, Inc. announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development.

-- Positive Anti-Cramping Effect of FLX-787 Reported in Recent MS study -- -- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing -- Conference Call Scheduled Today at 9:00 a.m. ET

AgeX Therapeutics, Inc. announced the award of a grant of approximately $386,000 from the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH).

Viking Therapeutics, Inc. announced that the company will release financial results for the first quarter of 2018 after the market close on Wednesday, May 9, 2018.

IQVIA Holdings Inc. reported financial results for the quarter ended March 31, 2018.

AbbVie will participate in the 2018 Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018.

Heska Corporation announced that Kevin Wilson, Chief Executive Officer and President, along with key members of the executive leadership team, will host an Analyst and Investor Day on Tuesday, May 15, 2018 from 8:00 a.m. to 1:30 p.m. ET on the 27th floor at Convene, 730 Third Avenue, (Between 45th & 46th Streets), in New York City.

Henry Schein, Inc. (Nasdaq: HSIC) today announced that Brad Connett has been named President of Henry Schein’s U.S. Medical Group.

SAM Medical today announced it is conducting a voluntary international recall of all unused SAM XT Extremity Tourniquets (SAM XT)

Rubius Therapeutics, a biotechnology company pioneering the development of a versatile new class of ready-to-use cellular therapies, today announced the appointment of Jonathan R. Symonds, CBE, to its board of directors.